Aquestive Therapeutics is a pharmaceutical company. Co. is improving medicines to solve patients' problems with care and provide transformative products to improve their lives. Co. is developing pharmaceutical products that deliver molecules through alternative administrations to invasive and inconvenient standard of care therapies. Co. also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, like PharmFilm®. Co. is developing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. Co. has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). The AQST average annual return since 2018 is shown above.
The Average Annual Return on the AQST average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AQST average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AQST average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free AQST Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
